122 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available Omegaven Expanded Access Protocol
Condition: Parenteral Nutrition Associated Liver Disease
Intervention: Drug: Omegaven
2 Unknown  Second Line Therapy to Treat Age-Related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
Condition: Age Related Macular Degeneration
Interventions: Drug: Visudyne;   Drug: Lucentis;   Drug: Dexamethasone
3 Available Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Condition: Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven 10%
4 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation
5 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
6 Available TX2® Low Profile TAA Endovascular Graft
Conditions: Aortic Aneurysm;   Penetrating Ulcer;   Vascular Disease
Intervention: Device: Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
7 Available Expanded Access Study of Amifampridine Phosphate in LEMS, Congenital Myasthenic Syndrome, or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
8 Available Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
9 Unknown  Expanded Access Protocol Using I131-MIBG
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
10 Available Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);   Juvenile Dermatomyositis (JDM);   Stimulator of Interferon Genes (STING)-Associated Vasculitis With Onset in Infancy (SAVI)
Intervention: Drug: Baricitinib
11 Available A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir (BMS-790052);   Drug: Sofosbuvir
12 Available Dextromethorphan Added on for the Patients With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Dextromethorphan
13 Unknown  Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Conditions: Leishmaniasis, Cutaneous;   Leishmaniasis, Mucocutaneous
Intervention: Drug: sodium stibogluconate (Pentostam)
14 Available Osteopathic Approach Into Neonatology Ward: the NE-O Model
Condition: The Focus of the Study is to Provide a Guideline on Osteopathic Approach in Treating Hospitalized Newborns.
Intervention: Other: Osteopathic Manipulative Treatment
15 Available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
16 Available Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
17 Available Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion
Conditions: Infection, Soft Tissue;   Infection, Wound;   Cellulitis;   Foot Ulcer, Diabetes
Interventions: Drug: Cefazolin;   Device: Silberg Tissue Preparation System
18 Available Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (BAY73-4506)
19 Available Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies
Conditions: Dravet Syndrome;   Epileptic Encephalopathies Associated With SCN1A Mutations
Intervention: Drug: Stiripentol
20 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years